Training Example: VEMLIDY (Gilead Sciences) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

VEMLIDY (Gilead Sciences)

(https://vemlidy.com) 📸 Data Snapshot: May 26, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Chronic Hep B Treatment | VEMLIDY® (tenofovir alafenamide) (https://vemlidy.com)
Title

Chronic Hep B Treatment | VEMLIDY® (tenofovir alafenamide)

Meta

VEMLIDY® is a prescription medication used to treat chronic hepatitis B virus in adults with stable liver disease. See Important Safety Information and important warnings on this site.

H1 Find your chronic hepatitis B treatment path
H5 Tap for Important Safety Information about VEMLIDY, including important warnings on worsening of hepatitis B virus infection.
H5 What should i tell my healthcare provider before taking vemlidy?
H5 What are the possible side effects of vemlidy?
H6 You are about to leave VEMLIDY.com
H6 IMPORTANT SAFETY INFORMATION
NAV_HEADER_REPEATED ISI (https://vemlidy.com/isi/)
Title

ISI

H4 WHAT IS VEMLIDY?
H4 Important Safety Information
H4 WHAT IS VEMLIDY?
H5 What is the most important information I should know about VEMLIDY?
H5 What should i tell my healthcare provider before taking vemlidy?
H5 What are the possible side effects of vemlidy?
H6 You are about to leave VEMLIDY.com
NAV_HEADER_REPEATED_BODY_FOOTER Real Stories and Resources | VEMLIDY® (tenofovir alafenamide) (https://vemlidy.com/stories-and-resources/)
Title

Real Stories and Resources | VEMLIDY® (tenofovir alafenamide)

Meta

Hear from real patients taking VEMLIDY® and find resources to help you learn more. See Important Safety Information and important warnings on this site.

H1 WHAT IS VEMLIDY?
H2 Transcript
H2 Transcript
H5 Tap for Important Safety Information about VEMLIDY, including important warnings on worsening of hepatitis B virus infection.
H5 What should i tell my healthcare provider before taking vemlidy?
H5 What are the possible side effects of vemlidy?
H6 You are about to leave VEMLIDY.com
H6 IMPORTANT SAFETY INFORMATION
NAV_HEADER_REPEATED_BODY_FOOTER VEMLIDY® Co-pay Savings Program | VEMLIDY® (tenofovir alafenamide) (https://vemlidy.com/savings/)
Title

VEMLIDY® Co-pay Savings Program | VEMLIDY® (tenofovir alafenamide)

Meta

Do you need help understanding your health insurance and Gilead medication costs for VEMLIDY®? Learn more today about co-pay support and access. See Important Safety Information and important warnings on this site.

H1 Enroll today to see if you are eligible for savings
H5 Tap for Important Safety Information about VEMLIDY, including important warnings on worsening of hepatitis B virus infection.
H5 What should i tell my healthcare provider before taking vemlidy?
H5 What are the possible side effects of vemlidy?
H6 You are about to leave VEMLIDY.com
H6 IMPORTANT SAFETY INFORMATION
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://vemlidy.com) Chronic Hep B Treatment | VEMLIDY® (tenofovir alafenamide)
[H6]

[H6] You are about to leave VEMLIDY.com

Continue enjoying moments with loved ones, while treating your chronic hepatitis B
See why VEMLIDY could be right for you

[IMG: Family cooking moment]
IT'S ABOUT THE MOMENTS

[H1] Find your chronic hepatitis B treatment path

Whether you are just starting to think about treatment or you have a VEMLIDY prescription, it’s important to know what to do next. Help determine your next steps by selecting the statement below that best describes you.

I am not in treatment for my chronic hepatitis B

×

Your first step is to partner with a doctor or liver specialist who will help determine whether treatment is right for you.

Learn the risks of not treating hep B
See VEMLIDY results
Hear from real VEMLIDY patients

I want to know why VEMLIDY may be right for me

×

If you’re interested in VEMLIDY, talking to your doctor is the best place to start. Asking the right questions can help create the treatment plan that’s right for you.

See how VEMLIDY works
Consider bone and renal safety
Hear from real VEMLIDY patients

My doctor has already prescribed VEMLIDY

×

If you and your doctor have decided that VEMLIDY is right for you, staying on track is an important part of your treatment journey.

Get tips for taking VEMLIDY
Explore safety and side effects
Learn about savings and support
1850 chars
SUB-PAGE (https://vemlidy.com/isi/) ISI
[H6]

[H6] You are about to leave VEMLIDY.com

Important Safety Information

[H4]
WHAT IS VEMLIDY?
VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults with stable (compensated) liver disease.
VEMLIDY may lower the amount of HBV in your body.
VEMLIDY may improve the condition of your liver.

[H4]
Important Safety Information
[H5]
What is the most important information I should know about VEMLIDY?
VEMLIDY can cause serious side effects, including:
Worsening of hepatitis B virus (HBV) infection. Your HBV infection may get worse (flare-up) if you take VEMLIDY and then stop taking it. A “flare-up” is when your HBV infection suddenly returns in a worse way than before. Do not stop taking VEMLIDY without first talking to your healthcare provider, as they will need to monitor your health regularly to check your liver.
[H5]
What should i tell my healthcare provider before taking vemlidy?
All of your medical conditions, including if you have end stage renal disease (ESRD) or HIV-1 infection. Your healthcare provider may test you for HIV infection before starting VEMLIDY. If you have HIV and only take VEMLIDY, the HIV virus may develop resistance and become harder to treat.
If you are pregnant or plan to become pregnant. It is not known if VEMLIDY will harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with VEMLIDY.
If you are breastfeeding or plan to breastfeed. VEMLIDY may pass into your breast milk. Talk with your healthcare provider about the best way to feed your baby.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how VEMLIDY works. Keep a list of all your medicines and show it to your healthcare provider and pharmacist. Do not start a new medicine without telling your healthcare provider. Ask your healthcare provider if it is safe to take VEMLIDY with all of your other medicines.
[H5]
What are the possible side effects of vemlidy?
New or worse kidney problems, including kidney failure. Your healthcare provider should do blood and urine tests to check your kidneys when starting and during treatment with VEMLIDY. Your healthcare provider may tell you to stop taking VEMLIDY if you develop new or worse kidney problems.
Too much lactic acid in your blood (lactic acidosis), which is a serious but rare medical emergency that can lead to death. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feeling dizzy or lightheaded, or a fast or abnormal heartbeat.
Severe liver problems, which in rare cases can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain.
The most common side effect of VEMLIDY is headache.
These are not all the possible side effects of VEMLIDY. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
[H4]
WHAT IS VEMLIDY?
VEMLIDY is a prescription medicine used to treat chronic (long-lasting) hepatitis B virus (HBV) in adults with stable (compensated) liver disease.
VEMLIDY may lower the amount of HBV in your body.
VEMLIDY may improve the condition of your liver.
Click here for Important Facts about VEMLIDY, including important warnings.
3907 chars
SUB-PAGE (https://vemlidy.com/stories-and-resources/) Real Stories and Resources | VEMLIDY® (tenofovir alafenamide)
[H6]

[H6] You are about to leave VEMLIDY.com

VEMLIDY stories and resources

Real VEMLIDY patients share their stories

Hear from others about why they decided to take VEMLIDY, what starting treatment was like, and how they stay on track with their routine.

“VEMLIDY was easy to fit into my life. It’s just a pill, and it’s tiny, and I take it once a day with food.” – Betsy

[H2]

Transcript

[Betsy]I’m Betsy. I’m a mother of four. My husband and I both work full time, and we are constantly running around.
We do competitive cheer, wrestling, soccer, ballet, sometimes basketball, and it’s a very full and fun life, and it is very busy.
I was diagnosed with hepatitis B in 2007. Right after I found out I was pregnant, they did a routine blood test and discovered it then. I didn’t have any symptoms of hep B. The referring physician kind of just sent me on my way, told me it was no big deal, so I just didn’t really ever think about it.
So, about 14 years later, my mom was getting just a random scan, and they found a tumor on her liver. It was diagnosed as HCC—hepatocellular carcinoma.
I started doing some research. I came across hep B over and over, and the doctor did confirm that the cancer was a result of the hepatitis B. We realized that my mom probably had hep B for a really long time, and we had no idea.
When we found out that she had cancer, I was devastated. I can’t imagine life without my mom. She is everything to me.
Around that time, I consulted with my GI. My hep B levels were low, so we didn’t really worry about it, but months later, I was feeling so tired all the time. I couldn’t get through a full day. I had to start taking naps.
I was so tired that I started forgetting when games were. I was beginning to miss everyday moments like helping the kids with their homework or sending them off to school before they went to the bus just saying, “I love you.” So, that was hard.
So, I finally followed up about a year later, because things were busy, and found out that my hep B levels were really high, and my liver enzyme levels were also very high.
I didn’t realize that my numbers could jump so quickly within just a few months. I was 38 years old. I knew I had to do something about my hep B.
I work in the pharmaceutical industry, so I knew where to look and what I was looking for in a treatment.
My doctor and I talked about many different options, and we decided that VEMLIDY was the right treatment for me.
She made sure that I understood that VEMLIDY wasn’t a cure, but it could help lower the amount of hep B in my body, and it could improve the condition of my liver.
My doctor and I discussed any other kind of medications that I was taking that might interact with VEMLIDY.
She told me that the most common side effect of VEMLIDY is headache.
Together we decided to move forward with VEMLIDY.
After just months of taking VEMLIDY, my doctor told me that my hep B virus levels were undetectable, and my liver enzyme levels were back into the normal range!
I felt that I could finally enjoy those everyday moments with my kids, and I could be there for them.
Of course, this is just my experience. Everybody’s experience with VEMLIDY may be different.
If you’re living with hep B, I think it’s important to know that you can do something about it and to talk to your doctor to see if VEMLIDY is the right option for you.
It was easy to fit into my life. It’s just a pill, and it’s tiny, and I take it once a day with food. VEMLIDY is kind of a no-brainer for me.
Initially, my doctor assumed that VEMLIDY wouldn’t be covered by my insurance, but we found out later that it was covered, and I was eligible for the co-pay coupon, so my co-pay ended up being zero!
[voiceover]
VEMLIDY is a prescription medicine used to treat chronic hepatitis B virus infection in adults with stable liver disease.
Before starting VEMLIDY, your doctor will test if you have HIV infection.
If you have both HBV and HIV, and only take VEMLIDY, the HIV virus may develop resistance and become harder to treat.
Serious side effects can occur, including kidney problems and kidney failure. Your doctor will test your kidneys when starting and during treatment.
Rare, life-threatening side effects include a build-up of lactic acid and liver problems.
Tell your doctor if you are or plan to be pregnant or breastfeeding as VEMLIDY may pass into your breastmilk, have HIV infection, kidney disease, and about all the medicines and supplements you take.
Do not stop taking VEMLIDY without talking to your doctor as the hepatitis B may get worse if you stop treatment.
The most common side effect was headache.
Ask your doctor if VEMLIDY is right for you.
Please see Important Safety Information for important warning on worsening of hepatitis B virus infection.
[Betsy]
My doctor discussed how important it was to stay on VEMLIDY and to make sure I take it every day so that we could keep my hep B levels low.
I’m not just staying on VEMLIDY for me. I’m staying on VEMLIDY for everybody that I love.
I’m staying on VEMLIDY because of my family and because I want to do the things that I am capable of doing.
There’s a lot ahead of us. I’m excited for the school graduations and for the dances and the happy moments and the sad moments.
I just want to keep enjoying the moments that matter.

“I switched to VEMLIDY, which is covered by my insurance. My doctor told me about the Co-pay Coupon Program. I was able to enroll, and my co-pay is $0.” – Frank

[H2]

Transcript

[Frank]
I’m Frank. I’m 56 years old.
I live in Fountain Valley.
I am married. I have three daughters.
I'm active and I love to exercise outside, and it's easy to do where I live in Southern California.
I'm originally from South Vietnam and my brother and I left when I was only nine.
We left on a wooden boat with nothing but clothes on our back.
I was very scared and we didn't know where we were going and we weren't sure we were ever going to see my parents again.
Thankfully, I had my older brother with me, because seeing his determination helped me build my own.
My childhood shaped me into who I am.
I was diagnosed with chronic hepatitis B in 2014, when I was 47.
When I was diagnosed, I was jaundiced. I was rushed to the hospital.
They ran a series of blood tests and told me that I had chronic hepatitis B.
Before I was diagnosed, I didn't have any symptoms.
I hadn't been sick before; it was a total shock.
I was worried that I wouldn't be able to support my wife and my family.
I was afraid of missing out on the moments that matter.
I asked my doctor for his recommendation.
He told me it was really important for me to start treatment right away to lower my hep B virus level and improve my liver health.
I had trouble swallowing my first medication and I skipped it a lot.
I didn't take my hep B medication as much, so my hep B virus level went even higher than when I was originally diagnosed.
Having chronic hep B made me very tired and sometimes it was very hard for me to find the energy to work out.
My first hep B pill was not right for me.
I reached out to my doctor and he recommended VEMLIDY in 2017 and I switched.
I've been taking VEMLIDY daily ever since.
The VEMLIDY pill is small and easy to take.
It works well for me and it fits into my daily routine. I take it every day with food.
VEMLIDY has become a regular part of my daily life.
I'm grateful that my doctor was open to having a conversation about my medication.
I'm happy that my doctor recommended VEMLIDY for me.
My doctor and I discussed any other kinds of medication that I was taking that might interact with VEMLIDY that may cause side effects and affect how VEMLIDY works.
Before starting VEMLIDY, my doctor also told me about common side effects like headaches, and some other serious side effects that can occur, including kidney problems and kidney failure.
I appreciate that there are saving and support options available for VEMLIDY. For my previous medication, I had to pay a co-pay every month.
But then I switched to VEMLIDY, which is covered by my insurance. My doctor told me about the Co-pay Coupon Program. I was able to enroll, and my co-pay is zero.
Every six months, I go to my doctor to get blood tests done to check my hep B virus level and my liver enzymes.
VEMLIDY helps me manage my hep B.
My hep B levels were undetectable within months of starting VEMLIDY and have stayed that way since.
My liver enzymes were within the normal range, too.
I think it's important for people to know about hep B and not be afraid.
I want my friends and other people like me to feel like they can speak up about treating hep B and know they are not alone.
[voiceover]
VEMLIDY is a prescription medicine used to treat chronic hepatitis B virus infection in adults with stable liver disease.
Before starting VEMLIDY, your doctor will test if you have HIV infection.
If you have both HBV and HIV, and only take VEMLIDY, the HIV virus may develop resistance and become harder to treat.
Serious side effects can occur, including kidney problems and kidney failure. Your doctor will test your kidneys when starting and during treatment.
Rare, life-threatening side effects include a build-up of lactic acid and liver problems.
Tell your doctor if you are or plan to be pregnant or breastfeeding as VEMLIDY may pass into your breastmilk, have HIV infection, kidney disease, and about all the medicines and supplements you take.
Do not stop taking VEMLIDY without talking to your doctor as the hepatitis B may get worse if you stop treatment.
The most common side effect was headache.
Ask your doctor if VEMLIDY is right for you.
Please see Important Safety Information for important warning on worsening of hepatitis B virus infection.
[Frank]
Switching to VEMLIDY has helped me manage my hep B really well.
I tell my children that there are challenges we must face, but when you wake up in the morning, be sure to thank God every day.
I want to continue enjoying the moments that matter with my family.

Starting or switching to VEMLIDY?

The following resources can help you learn more about VEMLIDY and take action.

Select All

Download All

Important Facts PDF

View

Download

Patient Brochure [English]

View

Download

Patient Brochure [繁體中文]

View

Download

Patient Brochure [한국어]

View

Download

Patient Brochure [Tiếng Việt]

View

Download

Patient Brochure [简体中文]

View

Download

Select All Download All

Important Facts PDF

View

Download

Patient Brochure [English]

View

Download

Patient Brochure [繁體中文]

View

Download

Patient Brochure [한국어]

View

Download

Patient Brochure [Tiếng Việt]

View

Download

Patient Brochure [简体中文]

View

Download
12235 chars
SUB-PAGE (https://vemlidy.com/savings/) VEMLIDY® Co-pay Savings Program | VEMLIDY® (tenofovir alafenamide)
[H6]

[H6] You are about to leave VEMLIDY.com

Financial support for VEMLIDY

Gilead is committed to helping you afford VEMLIDY

If you and your doctor have already decided that VEMLIDY is right for you, then Gilead is committed to helping you afford your medication, no matter the situation. Whether you have insurance or not, we may be able to help you in the following ways:

Determine if you are eligible to pay as low as $0 for your co-pay
Check eligibility

Identify potential sources of financial support if you have government insurance
See options

Identify potential sources of financial support if you are uninsured
See options

*Co-pay savings support is available for commercially insured eligible patients only. Additional restrictions apply. Subject to change; for full terms and conditions, visit www.mysupportpath.com/providers. This is not health insurance. Only accepted at participating pharmacies.
The VEMLIDY Co-pay Savings Program is here to help reduce your out-of-pocket costs

Out-of-pocket costs will be covered up to $6,000 each year, with no monthly limit
For eligible patients who have commercial insurance

Enroll here

† Co-pay savings support is available for commercially insured eligible patients only. Additional restrictions apply. Subject to change; for full terms and conditions, visit www.mysupportpath.com/providers. This is not health insurance. Only accepted at participating pharmacies.

†
Co-pay savings support is available for commercially insured eligible patients only. Additional
restrictions apply. Subject to change; for full terms and conditions, visit www.mysupportpath.com/providers. This
is not health insurance. Only accepted at participating pharmacies

[H1] Enroll today to see if you are eligible for savings

You’re enrolled in the VEMLIDY Co-pay Savings Program and your co-pay card is ready.

If you have any questions regarding your co-pay card, please call Support Path at 1-855-769-7284, Monday through Friday, from 9 AM to 8 PM, ET.
Download card

Co-pay Savings Program Benefits
Subject to the Gilead Support Path® Co-pay Savings Program (“Savings Program”) Terms and Conditions, this program provides the following financial assistance for the out-of-pocket costs for eligible commercially insured patients with a valid prescription:
Up to a maximum of $6,000 in cost-sharing assistance per calendar year with no monthly limit for the following product:
VEMLIDY® (tenofovir alafenamide 25 mg)
As described in the Savings Program Terms and Conditions, Gilead may reduce or discontinue the financial assistance available under the program if it determines the patient is subject to an “accumulator adjustment” or “co-pay maximizer” program.
If Gilead determines that a patient’s insurer (or its agent) has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Savings Program (sometimes called a “co-pay maximizer program”), unless prohibited by law, Gilead may reduce or discontinue the cost-sharing assistance available under the program after providing assistance in an amount not to exceed the lesser of the Affordable Care Act (ACA) maximum limit or current Savings Program limit.
If Gilead determines that a patient’s insurer (or its agent) has implemented a program that excludes the financial assistance provided under the Savings Program from counting towards the patient’s deductible or out-of-pocket cost limitations (sometimes called an “accumulator adjustment program”), unless prohibited by law, Gilead may reduce the cost-sharing assistance available under the program to a per claim maximum of $25. Please contact Support Path at 1-855-769-7284 to determine if additional cost-sharing assistance is available.
These program benefits are subject to change for any reason at any time without notice.
Gilead Support Path® Co-pay Savings Program Terms and Conditions:
The Gilead Support Path Co-pay Savings Program (“Savings Program”) provides financial assistance for the out-of-pocket costs to eligible commercially insured patients as described in the Savings Program Benefits above. Savings Program benefits are limited to financial assistance for patient cost-sharing for the applicable Gilead product only.
The Savings Program can be used only by eligible residents of the US, Puerto Rico, or US territories at participating eligible pharmacies in the US, Puerto Rico, or US territories. Product must be dispensed in the US, Puerto Rico, or US territories. Patients must be at least 18 years old to use the Savings Program themselves or to enroll in the Savings Program on behalf of a minor.
To use the Savings Program, the patient (or the authorized representative under federal or state law enrolling on behalf of the patient, as applicable) must personally complete the enrollment process for the Savings Program. Third-party payers, pharmacy benefit managers, or the agents of either, are prohibited from assisting patients with enrolling in the Savings Program. Any decision to enroll in the Savings Program must be made voluntarily by the patient.
The Savings Program is not insurance and is not intended to substitute for insurance. Uninsured and cash-paying patients are not eligible to use the Savings Program. The Savings Program benefit is valid only for prescriptions that are reimbursed by commercial insurance and is not valid for prescriptions that are eligible to be reimbursed:
in whole or in part by Medicare or a Medicare Part D plan, Medicaid, TRICARE, VA, DOD, Puerto Rico Government Health Insurance Plan, or any other state or federally funded healthcare benefit program (collectively, “Government Programs”); or
by commercial plans or other health or pharmacy benefit programs that reimburse for the entire cost of prescription drugs or prohibit the program’s use.
Patients who begin receiving prescription benefits from Government Programs at any time must notify Gilead of this fact by contacting Support Path at 1-855-769-7284 and will no longer be eligible to use the Savings Program.
The Savings Program is limited to one per person and is not transferable. No substitutions are permitted. This Savings Program is offered to, and intended for the sole benefit of, eligible patients and may not be utilized for the benefit of third parties, including, without limitation, third-party payers, pharmacy benefit managers, or the agents of either. If Gilead determines that a patient’s insurer has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Savings Program (sometimes called a “co-pay maximizer program”), unless prohibited by law, Gilead may reduce or discontinue the cost-sharing assistance available under the Savings Program after providing assistance in an amount not to exceed the lesser of the Affordable Care Act (ACA) out-of-pocket maximum or current Savings Program limit. If Gilead determines that a patient’s insurer has implemented a program that excludes the financial assistance provided under the Savings Program from counting towards the patient’s deductible or out-of-pocket cost limitations (sometimes called an “accumulator adjustment program”), unless prohibited by law, Gilead may reduce the cost-sharing assistance available under the Savings Program to a per claim maximum of $25. Patients may contact Support Path at 1-855-769-7284 to determine if additional cost-sharing assistance is available.
The Savings Program is only available with a valid prescription. No other purchase is necessary to redeem this offer.
The Savings Program cannot be combined with any other coupon, free trial, discount, prescription savings card, or other offer (including, without limitation, any program offered by a third-party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations). Patients are not eligible to use the Savings Program for a product if they are currently receiving free drug assistance through Gilead Sciences, Inc. (“Gilead”)’s patient assistance program for that product.
The Savings Program will not reimburse any payments made by Flexible Spending Account (FSA), Health Savings Account (HSA), Health Reimbursement Account (HRA), or any other payor, discount/co-pay program, or other offer.
Void where prohibited by law, taxed, or restricted.
Patient, pharmacist, and prescriber agree not to seek reimbursement for all, or any part of the benefit received by the patient through the Savings Program. Both patient and pharmacist are each individually responsible for reporting receipt of the saving benefit to any insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the Savings Program, as may be required.
It is illegal to sell, purchase, trade, or counterfeit, or offer to sell, purchase, trade, or counterfeit the Savings Program.
Certain information pertaining to your use of the Savings Program will be shared with Gilead, the sponsor of the program, and its affiliates. The information disclosed will include the patient co-pay ID, pharmacy demographics, prescriber information, and details relating to the claim, such as co-pay amount, insurance details, and the therapy received. For more information, please see Gilead’s Privacy Statement and Consumer Health Data Privacy Policy available at www.gilead.com.
Gilead Sciences reserves the right to terminate, rescind, revoke, or modify the Savings Program for any reason at any time without notice.
11113 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
2Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 0 0
/isi/ 0 0
/stories-and-resources/ 0 0
/savings/ 2 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/isi/ — no schema detected (entity gap)
/stories-and-resources/ — no schema detected (entity gap)
/savings/ — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: VEMLIDY (Gilead Sciences) (vemlidy.com)

https://vemlidy.com 📍 Industry: Medical Devices, Pharma & Biotech
38 BS / 100

VEMLIDY.com is a high-substance, compliant pharmaceutical site that is anchored by heavy regulatory requirements but weighed down by standard emotional marketing tropes. The BS score is kept low by the granular detail in the savings and safety sections, though the technical SEO and schema implementation are severely lacking. It successfully bridges the gap between patient emotion and clinical necessity without crossing into extreme hyperbole.

Info Density Power-words vs. Substance ratio.
8
27% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
3
15% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
9
45% BS
Commodity Fingerprint Detection of industry clichés/templates.
8
53% BS
Identity & Authority Expert verifiability & Schema depth.
10
67% BS

Implement Organization and Drug schema to provide technical authority and link to Gilead’s official corporate identity. Restructure the heading hierarchy to ensure the H1 is the first tag encountered by crawlers, moving the H6 exit warnings into a non-heading container. Add direct citations or links to peer-reviewed clinical trial results within the patient testimonial sections to provide immediate evidence for efficacy claims. Reduce the repetition of the Moments marketing language to increase the overall information density of the homepage.

The content perfectly aligns with the Pharma & Biotech category, specifically focusing on a prescription medication for chronic hepatitis B (HBV). The presence of mandatory Important Safety Information (ISI) and specific pharmacological details like tenofovir alafenamide 25 mg confirms this classification.

“The score of 38 is driven primarily by the high Information Density and Semantic Coherence pillars, which are strengthened by mandatory pharmaceutical disclosures. The score was penalized by the Identity and Authority pillar due to the complete lack of schema data and poor heading structure. Trust and Proof also contributed slightly to the BS score due to the reliance on anecdotal patient transcripts over direct clinical data summaries.”

Verified Analysis Date: May 26, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation